Literature DB >> 16140742

Attenuation of Marek's disease virus by deletion of open reading frame RLORF4 but not RLORF5a.

Keith W Jarosinski1, Nikolaus Osterrieder, Venugopal K Nair, Karel A Schat.   

Abstract

Marek's disease (MD) in chickens is caused by the alphaherpesvirus MD virus (MDV) and is characterized by the development of lymphoblastoid tumors in multiple organs. The recent identification and cloning of RLORF4 and the finding that four of six attenuated strains of MDV contained deletions within RLORF4 suggested that it is involved in the attenuation process of MDV. To assess the role of RLORF4 in MD pathogenesis, its coding sequence was deleted in the pRB-1B bacterial artificial chromosome clone. Additionally, RLORF5a was deleted separately to examine its importance for oncogenesis. The sizes of plaques produced by MDV reconstituted from pRB-1BdeltaRLORF5a (rRB-1BdeltaRLORF5a) were similar to those produced by the parental pRB-1B virus (rRB-1B). In contrast, virus reconstituted from pRB-1BDeltaRLORF4 (rRB-1BdeltaRLORF4) produced significantly larger plaques. Replication of the latter virus in cultured cells was higher than that of rRB-1B or rRB-1BdeltaRLORF5a using quantitative PCR (qPCR) assays. In vivo, both deletion mutants and rRB-1B replicated at comparable levels at 4, 7, and 10 days postinoculation (p.i.), as determined by virus isolation and qPCR assays. At 14 days p.i., the number of PFU of virus isolated from chickens infected with rRB-1BdeltaRLORF4 was comparable to that from chickens infected with highly attenuated RB-1B and significantly lower than that from rRB-1B-infected birds. The number of tumors and kinetics of tumor production in chickens infected with rRB-1BdeltaRLORF5a were similar to those of P2a chickens infected with rRB-1B. In stark contrast, none of the chickens inoculated with rRB-1BdeltaRLORF4 died up to 13 weeks p.i.; however, two chickens had tumors at the termination of the experiment. The data indicate that RLORF4 is involved in attenuation of MDV, although the function of RLORF4 is still unknown.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140742      PMCID: PMC1212595          DOI: 10.1128/JVI.79.18.11647-11659.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Expansion of a unique region in the Marek's disease virus genome occurs concomitantly with attenuation but is not sufficient to cause attenuation.

Authors:  R F Silva; S M Reddy; B Lupiani
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

2.  Marek's disease virus-encoded Meq gene is involved in transformation of lymphocytes but is dispensable for replication.

Authors:  Blanca Lupiani; Lucy F Lee; Xiaoping Cui; Isabel Gimeno; Amy Anderson; Robin W Morgan; Robert F Silva; Richard L Witter; Hsing-Jien Kung; Sanjay M Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

3.  Open reading frame L1 of Marek's disease herpesvirus is not essential for in vitro and in vivo virus replication and establishment of latency.

Authors:  K A Schat; B J Hooft van Iddekinge; H Boerrigter; P H O'Connell; G Koch
Journal:  J Gen Virol       Date:  1998-04       Impact factor: 3.891

4.  Expression of cytokine genes in Marek's disease virus-infected chickens and chicken embryo fibroblast cultures.

Authors:  Z Xing; K A Schat
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

5.  Characterization of a Marek's disease virus BamHI-L-specific cDNA clone obtained from a Marek's disease lymphoblastoid cell line.

Authors:  K Ohashi; W Zhou; P H O'Connell; K A Schat
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

6.  The structure of Marek disease virus DNA: the presence of unique expansion in nonpathogenic viral DNA.

Authors:  K Fukuchi; A Tanaka; L W Schierman; R L Witter; M Nonoyama
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

7.  Reconstitution of Marek's disease virus serotype 1 (MDV-1) from DNA cloned as a bacterial artificial chromosome and characterization of a glycoprotein B-negative MDV-1 mutant.

Authors:  D Schumacher; B K Tischer; W Fuchs; N Osterrieder
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

8.  Alterations in DNA sequence and RNA transcription of the Bam HI-H fragment accompany attenuation of oncogenic Marek's disease herpesvirus.

Authors:  N Ross; M M Binns; M Sanderson; K A Schat
Journal:  Virus Genes       Date:  1993-02       Impact factor: 2.332

9.  Molecular analysis of the glycoprotein C-negative phenotype of attenuated Marek's disease virus.

Authors:  M R Wilson; R A Southwick; J T Pulaski; V L Tieber; Y Hong; P M Coussens
Journal:  Virology       Date:  1994-03       Impact factor: 3.616

10.  Isolation and characterization of Marek's disease virus (MDV) cDNAs mapping to the BamHI-I2, BamHI-Q2, and BamHI-L fragments of the MDV genome from lymphoblastoid cells transformed and persistently infected with MDV.

Authors:  Q Peng; M Zeng; Z A Bhuiyan; E Ubukata; A Tanaka; M Nonoyama; Y Shirazi
Journal:  Virology       Date:  1995-11-10       Impact factor: 3.616

View more
  54 in total

1.  The Herpesviridae Conserved Multifunctional Infected-Cell Protein 27 (ICP27) Is Important but Not Required for Replication and Oncogenicity of Marek's Disease Alphaherpesvirus.

Authors:  Nagendraprabhu Ponnuraj; Yung-Tien Tien; Widaliz Vega-Rodriguez; Andrea Krieter; Keith W Jarosinski
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  The ORF012 gene of Marek's disease virus type 1 produces a spliced transcript and encodes a novel nuclear phosphoprotein essential for virus growth.

Authors:  Timo Schippers; Keith Jarosinski; Nikolaus Osterrieder
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  Marek's disease virus expresses multiple UL44 (gC) variants through mRNA splicing that are all required for efficient horizontal transmission.

Authors:  Keith W Jarosinski; Nikolaus Osterrieder
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

4.  Comparative sequence analysis of a highly oncogenic but horizontal spread-defective clone of Marek's disease virus.

Authors:  Stephen J Spatz; Yuguang Zhao; Lawrence Petherbridge; Lorraine P Smith; Susan J Baigent; Venugopal Nair
Journal:  Virus Genes       Date:  2007-08-25       Impact factor: 2.332

5.  Clustering of mutations within the inverted repeat regions of a serially passaged attenuated gallid herpesvirus type 2 strain.

Authors:  Stephen J Spatz; Cary Rue; Daniel Schumacher; Nikolaus Osterrieder
Journal:  Virus Genes       Date:  2008-05-31       Impact factor: 2.332

6.  Further analysis of Marek's disease virus horizontal transmission confirms that U(L)44 (gC) and U(L)13 protein kinase activity are essential, while U(S)2 is nonessential.

Authors:  Keith W Jarosinski; Nikolaus Osterrieder
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

7.  Role of the short telomeric repeat region in Marek's disease virus replication, genomic integration, and lymphomagenesis.

Authors:  Annachiara Greco; Nadine Fester; Annemarie T Engel; Benedikt B Kaufer
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

8.  Molecular and pathogenicity characterization of Gallid herpesvirus 2 newly isolated in China from 2009 to 2013.

Authors:  Yan-Ping Zhang; Hong-Chao Lv; Ke-Yan Bao; Yu-Long Gao; Hong-Lei Gao; Xiao- le Qi; Hong-Yu Cui; Yong-Qiang Wang; Kai Li; Li Gao; Xiao-Mei Wang; Chang-Jun Liu
Journal:  Virus Genes       Date:  2015-11-26       Impact factor: 2.332

9.  Viral control of vTR expression is critical for efficient formation and dissemination of lymphoma induced by Marek's disease virus (MDV).

Authors:  Najat Chbab; Annemarie Egerer; Inês Veiga; Keith W Jarosinski; Nikolaus Osterrieder
Journal:  Vet Res       Date:  2010-04-29       Impact factor: 3.683

10.  Herpesvirus telomerase RNA(vTR)-dependent lymphoma formation does not require interaction of vTR with telomerase reverse transcriptase (TERT).

Authors:  Benedikt B Kaufer; Sascha Trapp; Keith W Jarosinski; Nikolaus Osterrieder
Journal:  PLoS Pathog       Date:  2010-08-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.